Featured Speakers

  • Anna JonebringSenior research scientist, iPSC/Primary cell/Stem Cell and Assay Development Team AstraZeneca

  • Rakesh K. JainDirector, Edwin L. Steele Laboratory of Tumor Biology Massachusetts General Hospital Cancer Center

  • Roberto IaconeGroup Head, Stem Cell, Cardiovascular & Metabolism Roche

  • Janet DavisScientific Director Janssen

Share |
View all...

Develop, use and validate your stem cell derived models and assays.

Innovation has been sweeping across the stem cell field over the last 6-12 months. It’s clear that pharma and biotech leaders are making huge progress in differentiation, modeling, screening and predictive toxicology.

How are you keeping up with this innovation? What tools and solutions do you need to improve and validate your stem cell derived assays?

You’ve said that it’s through discussion and debate that the field can drive forward the practical utility of stem cell derived models.

The 3rd Stem Cells for Drug Developers meeting will bring together experts from AstraZeneca, Harvard Medical School, Novartis and many others who will help you tackle the key issues to develop, use and validate your stem cell derived models and assays.

So whether you’re developing assays for compound screening or working to improve differentiation protocols, the 3rd Stem Cells for Drug Developers is the place to learn, network and discuss how to achieve these goals.

On the agenda for 3rd Stem Cells for Drug Developers:

  • Find out how AstraZeneca, BMS, Pfizer, Novartis and Genentech are successfully integrating stem cell derived models into drug discovery to predict toxicity and improve drug screening efficiency
  • Understand what novel approaches Harvard Medical School and The Buck Institute are using to create complex 3D structures in order to mimic tissue architecture and proper cell-cell interactions
  • Learn from Abbott and Sanofi about what steps you need to take to validate your models and assays as being better than current gold standards and how to undertake a validation exercise
  • Regeneron, Medical College of Wisconsin and GSK  will discuss how they are tuning stem cell derived cells into adult phenotypes and  recapitulating the complex pathophysiology of diseases to reveal possible therapeutic targets
  • Get involved in the round table discussions and debate with your peers what differentiated cell types should be prioritized in the future, the need to create a standardized method for generating cell lines and how to improve access to patient samples

Who will attend?

  • Pharmaceutical companies looking to better understand how to overcome current barriers in stem cell research and how to practically use stem cell-derived cells for compound screening and toxicity testing
  • Biotechs interested in showcasing their stem cell work to large pharma and other drug developers
  • Stem cell and technology providers who are able to provide solutions to the problems experienced by the field
  • Not for profit institutes who are interested to see how research is being translated into drug development and those who are looking for collaborations and funding opportunities

What’s next?

There are a number of ways you can register:

Book online; call +1 212 537 5898 or email: register@hansonwade.com

Don't waste time! Get the best rates by securing your place now.